Cellular Intelligence has acquired Novo Nordisk\u2019s clinical-stage Parkinson\u2019s cell therapy programme, combining AI-native manufacturing capabilities with regenerative medicine expertise to accelerate development, scalability, and global commercialisation efforts.<\/p>\n
Cellular Intelligence<\/a> has entered into an agreement with Novo Nordisk<\/a> to acquire global rights to the pharmaceutical giant\u2019s clinical-stage cell therapy programme for Parkinson\u2019s disease.<\/p>\n The agreement marks a significant milestone for Cellular Intelligence as it looks to apply its proprietary AI-native platform to accelerate clinical development, manufacturing, and the path towards commercialisation for the programme, which is currently in a first-in-human Phase 1\/2 clinical trial.<\/p>\n Importantly, the therapy has already received FDA Fast Track Designation and IND clearance for further clinical development, underscoring its potential as a meaningful disease-modifying treatment for people living with Parkinson\u2019s disease.<\/p>\n As part of the arrangement, Novo Nordisk will also make an equity investment into Cellular Intelligence and remain eligible for future milestones and royalties.<\/p>\n \u201cThis cell therapy Parkinson\u2019s programme is truly innovative and exemplifies the powerful convergence of exciting academic discovery with the uncompromising quality of a global pharmaceutical leader, and we are honoured to carry the programme into its next chapter. Optimising and scaling complex cell therapy programmes to reach patients globally is exactly the challenge our AI-native platform was built to solve\u201d<\/p>\n Micha Breakstone, Ph.D<\/a>., co-Founder and CEO of Cellular Intelligence<\/a><\/p>\n At the centre of the collaboration is Cellular Intelligence\u2019s AI-native platform, which combines proprietary multiplexing technologies with a foundation model trained on data spanning millions of unique perturbation conditions.<\/p>\n The company believes this approach can significantly compress traditional cell therapy development and manufacturing timelines whilst reducing costs and improving scalability \u2013 key barriers that have historically limited wider commercial adoption within regenerative medicine.<\/p>\n The Parkinson\u2019s programme itself focuses on an allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy, designed to address the growing global burden of neurodegenerative disease.<\/p>\n Beyond the immediate programme, Cellular Intelligence also expects the clinical and manufacturing data generated through development to further strengthen its foundation model, potentially enabling wider applications across cell therapy and regenerative medicine in the future.<\/p>\n \u201cFinding the right steward for the programme was critical, and we are convinced that Cellular Intelligence has the capabilities needed to advance it further. The convergence of developmental biology and genomics, and the possibility of combining this with AI on a single platform, provide an exciting opportunity in medicine in general, and for the cell therapy field in particular\u201d<\/p>\n Jacob Petersen<\/a>, Senior Vice President, Global Research, Novo Nordisk<\/a><\/p>\n